CANADIAN NATIONAL RAILWAY CO (CNI): what the price assumes

boothcheck covers CANADIAN NATIONAL RAILWAY CO (CNI) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-08-08.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/CNI

Headline

FieldValue
TickerCNI
CompanyCANADIAN NATIONAL RAILWAY CO
Sector / IndustryIndustrials
Current price$126.01/sh

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Multiple paid19x operating income

How unusual the bet is: n/a

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset7.68x4expensive
Earnings5.37x1expensive
Relative7.21x3expensive
Growth2.71x2expensive

Families that call it expensive: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.3%); the inversion above states its own rate.

Per-Model Detail (n=10)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00noFCF base $0.9B, growth -10% (input: historical growth), terminal g 0.5%, WACC 8.3%, 5yr projection
DCF Exit MultipleGrowth$115.921.09xyesExit EV/EBITDA: 43.7x / 45.7x / 47.7x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$64.631.95xyesP/E 36.52x (blended: static sector reference 20x + trailing (TTM) 75x), scenarios: 31.0x / 36.5x / 42.1x (bear / base = reference held flat / bull), EV/EBITDA 22.82x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$18.156.94xyesBV/sh $25.86, ROE (TTM) 6.5%, ke 9.3%
Two-Stage Excess ReturnAsset$14.978.42xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$29.084.33xyesRev $4.3B, growth -15% (input: historical growth; tapered), Terminal P/S: 6.8x / 8.0x / 9.2x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelativeno
Margin TrajectoryGrowthno
Earnings Power ValueEarningsno
Residual IncomeAsset$14.538.67xyesBV $25.86 + 5yr PV of (ROE (TTM) 6.5% − Kₑ 9.3%) × BV; BV grows 4.2%/yr
Graham NumberAsset$35.523.55xyes√(22.5 × EPS $2.17 × BVPS $25.86) — Graham's conservative floor
EV/EBITDA RelativeRelative$17.477.21xyesEBITDA $2.03B × sector EV/EBITDA 13.0x
FCF YieldEarnings$0.0112601.00xyesFCF $904.4M / Kₑ 9.3% — zero-growth perpetuity (excluded from median)
SBC-Adj FCF YieldEarningsno
Ben Graham FormulaEarnings$1.8269.24xyesEPS $2.17 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAssetno
P/Sales SectorRelative$14.118.93xyesRevenue $4.33B × sector P/S 2.0x
PEG Fair ValueRelativeno
Earnings YieldEarnings$23.455.37xyesEPS $2.17 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Solvency

FieldValue
Net debt$15.1b
Net debt / NOPAT (after-tax)4.03x
Net debt / operating income (pre-tax)3.19x
Interest coverage7.2x
Burning cashno

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive CNI report on boothcheck